Diane Schiller

We are an agile, specialized team with a track record of €300m+ invested in tech across Europe and the US, backing several of the largest European exits including Kyriba, LumApps, Preligens, 360Learning, and Planisware. We invest €5–15m minority stakes in B2B software companies from €3m ARR. We help founders reach the scale and growth profile where they will find real liquidity, optionality, and strategic freedom. We come from and remain anchored by Wendel, a leading private assets firm with a pan-European footprint, managing over €50bn of assets.

YesWeHack is a leading Offensive Security and Exposure Management platform delivering integrated, API-based solutions to secure organisations’ growing attack surfaces. Its human-in-the-loop model combines Bug Bounty, Autonomous Pentesting, Continuous Pentesting and unified vulnerability management to deliver agile, exhaustive security testing at scale. Customers include Louis Vuitton, Ferrero, the European Commission, Tencent and L’Oréal Groupe. ISO 27001-certified, CREST-accredited, and EU-hosted with full GDPR compliance.

AQEMIA is a drug invention company dedicated to novel medicines — never me-toos — tackling major diseases such as oncology. Our physics-based, generative AI platform invents drug candidates beyond the reach of traditional R&D, without dependence on experimental data. We are building a rapidly expanding portfolio of proprietary programs, alongside collaborations with top pharmaceutical companies. Multiple discovery successes are already achieved, with lead programs progressing through in vivo optimization. AQEMIA is part of the French Tech 120 program, which supports the most promising scale-ups in France with global impact potential. AQEMIA is member of the BioIndustry Association (BIA) and the Knowledge Quarter in London. AQEMIA is based in Paris (HQ) and London. We are growing and hiring! Discover our opportunities here: https://jobs.lever.co/aqemia.com Discover the roles and behind-the-scenes at AQEMIA: https://www.welcometothejungle.com/fr/companies/aqemia

Brigad is an app that enables self-employed professionals and businesses in Hospitality and Healthcare to connect for short-term missions. The community of talents is vetted by our teams to ensure highly-qualified and reliable professionals are able to accept the missions proposed. As a business, post a mission in a few clicks and talented pros will receive your proposition. Self-employed professionals choose the missions which suit them best, ensuring they arrive motivated, prepared and energised for the mission. Brigad launched in 2016 with the mission "to make work accessible and attractive to all" and is currently available in major cities in France and in the UK.

We are an agile, specialized team with a track record of €300m+ invested in tech across Europe and the US, backing several of the largest European exits including Kyriba, LumApps, Preligens, 360Learning, and Planisware. We invest €5–15m minority stakes in B2B software companies from €3m ARR. We help founders reach the scale and growth profile where they will find real liquidity, optionality, and strategic freedom. We come from and remain anchored by Wendel, a leading private assets firm with a pan-European footprint, managing over €50bn of assets.

YesWeHack is a leading Offensive Security and Exposure Management platform delivering integrated, API-based solutions to secure organisations’ growing attack surfaces. Its human-in-the-loop model combines Bug Bounty, Autonomous Pentesting, Continuous Pentesting and unified vulnerability management to deliver agile, exhaustive security testing at scale. Customers include Louis Vuitton, Ferrero, the European Commission, Tencent and L’Oréal Groupe. ISO 27001-certified, CREST-accredited, and EU-hosted with full GDPR compliance.

AQEMIA is a drug invention company dedicated to novel medicines — never me-toos — tackling major diseases such as oncology. Our physics-based, generative AI platform invents drug candidates beyond the reach of traditional R&D, without dependence on experimental data. We are building a rapidly expanding portfolio of proprietary programs, alongside collaborations with top pharmaceutical companies. Multiple discovery successes are already achieved, with lead programs progressing through in vivo optimization. AQEMIA is part of the French Tech 120 program, which supports the most promising scale-ups in France with global impact potential. AQEMIA is member of the BioIndustry Association (BIA) and the Knowledge Quarter in London. AQEMIA is based in Paris (HQ) and London. We are growing and hiring! Discover our opportunities here: https://jobs.lever.co/aqemia.com Discover the roles and behind-the-scenes at AQEMIA: https://www.welcometothejungle.com/fr/companies/aqemia

Brigad is an app that enables self-employed professionals and businesses in Hospitality and Healthcare to connect for short-term missions. The community of talents is vetted by our teams to ensure highly-qualified and reliable professionals are able to accept the missions proposed. As a business, post a mission in a few clicks and talented pros will receive your proposition. Self-employed professionals choose the missions which suit them best, ensuring they arrive motivated, prepared and energised for the mission. Brigad launched in 2016 with the mission "to make work accessible and attractive to all" and is currently available in major cities in France and in the UK.

Wendel is one of Europe’s leading listed investment firms. Regarding its principal investment strategy, the Group invests in companies which are leaders in their field, such as ACAMS, Bureau Veritas, Crisis Prevention Institute, Globeducate, IHS Towers, Scalian, Stahl and Tarkett. In 2023, Wendel initiated a strategic shift into third-party asset management of private assets, alongside its historical principal investment activities. In May 2024, Wendel completed the acquisition of a 51% stake in IK Partners, a major step in the deployment of its strategic expansion in third-party private asset management and also completed in March 2025 the acquisition of 72% of Monroe Capital. As of June 30, 2025, Wendel manages 39 billion euros on behalf of third-party investors, and c.6.2 billion euros invested in its principal investments activity.